Headlands Technologies LLC Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Headlands Technologies LLC lifted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 17.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,065 shares of the biopharmaceutical company's stock after purchasing an additional 2,883 shares during the quarter. Headlands Technologies LLC's holdings in Intra-Cellular Therapies were worth $1,592,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $96,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies in the third quarter valued at approximately $97,000. Quarry LP raised its stake in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $184,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ITCI shares. Piper Sandler restated a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research report on Saturday. They issued a "hold" rating for the company. Cantor Fitzgerald reiterated a "neutral" rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday. Finally, Mizuho cut Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $140.00 to $132.00 in a report on Monday, February 24th. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $106.23.

Remove Ads

Intra-Cellular Therapies Price Performance

NASDAQ ITCI remained flat at $131.87 during trading hours on Friday. The stock has a 50 day simple moving average of $129.62 and a two-hundred day simple moving average of $101.61. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. As a group, research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.